$VRAX Income Statement | Understand Stock

$VRAX

$1.19 -$0.03 (2.46%) Close

Financial Statements

In USD, except per-share amounts

	FY2026 12 months to Mar 31, 2026	FY2025 12 months to Mar 31, 2025	FY2024 12 months to Mar 31, 2024	FY2023 12 months to Mar 31, 2023	FY2022 12 months to Mar 31, 2022
Revenue
Cost of revenue
Gross profit (loss)
Operating expenses:
Sales and Marketing
General and administrative
Research & development
Impairment of intangible asset
Total operating expenses

Operating loss
Other income (expense):
Interest expense, net
Other income (expense), net
Foreign currency gain (loss), net
Total other income (expense), net
Loss before income taxes
Income tax benefit
Net loss
Net loss attributable to non-controlling interest
Net loss attributable to Virax Biolabs shareholders
Other comprehensive income (loss):
Foreign currency adjustment
Total Comprehensive loss
Comprehensive loss attributable to non-controlling interest
Comprehensive loss attributable to Virax Biolabs shareholders
Basic and diluted weighted average shares outstanding
Basic and diluted weighted average shares outstanding
Class A Shares
Class B Shares
Ordinary shares
Diluted ordinary shares

Basic and diluted net loss per share to Virax Biolabs shareholders*
Basic and diluted net loss per share
Class A Shares
Class B Shares
Basic net loss per share - Ordinary shares
Diluted net loss per share - Ordinary shares

Comments